{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T21:04:26Z","timestamp":1775509466064,"version":"3.50.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,7,5]],"date-time":"2024-07-05T00:00:00Z","timestamp":1720137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,5]],"date-time":"2024-07-05T00:00:00Z","timestamp":1720137600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Janssen Cilag France"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Ibrutinib is a Bruton\u2019s tyrosine kinase inhibitor indicated for the first-line treatment and relapse of chronic lymphocytic leukaemia (CLL), Waldenstr\u00f6m\u2019s macroglobulinemia (WM) and mantle cell lymphoma (MCL). This study aimed to describe the characteristics of CLL patients treated with ibrutinib and its effectiveness, safety, and treatment pattern in real life.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>All patients covered by the general health scheme (approximately 80% of the French population) with a first ibrutinib dispensation from August 1, 2017 (date of reimbursement in France) to December 31, 2020, were identified in the French National Health Insurance database (SNDS). An algorithm was developed to identify the disease (CLL, MCL or WM) for which ibrutinib was prescribed. This article focused on CLL patients. The time to next treatment (TTNT) was plotted using Kaplan\u2012Meier curves.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>During this period, 6,083 patients initiated ibrutinib, among whom 2,771 (45.6%) patients had CLL (mean age of 74 years; 61% of men). At ibrutinib initiation, 46.6% of patients had a cardiovascular comorbidity. Most patients (91.7%) were not hospitalized during the exposure period for one of the cardiovascular or bleeding events studied. Hospitalizations were more frequent in patients with a cardiovascular comorbidity (5.9% versus 11.0%, p-value\u2009&lt;\u20090.0001) and aged over 70 (5.9% versus 9.4%, p-value\u2009&lt;\u20090.0001). The median TTNT was not reached.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>This is one of the largest cohorts of ibrutinib-treated patients in the world. The profile of CLL patients treated with ibrutinib was in accordance with the marketing authorization and reimbursement. This study confirmed effectiveness and safety data.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00277-024-05859-w","type":"journal-article","created":{"date-parts":[[2024,7,5]],"date-time":"2024-07-05T03:33:53Z","timestamp":1720150433000},"page":"2969-2981","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["A retrospective observational study of ibrutinib in chronic lymphocytic leukaemia in a real-life setting in France using the national claims database (OSIRIS)"],"prefix":"10.1007","volume":"103","author":[{"given":"Sylvain","family":"Choquet","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clarisse","family":"Marchal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Floriane","family":"Deygas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marine","family":"Deslandes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nahid","family":"Macher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G\u00e9rard","family":"de Pouvourville","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Levy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,7,5]]},"reference":[{"key":"5859_CR1","unstructured":"American Cancer Society What Is Chronic Lymphocytic Leukemia? https:\/\/www.cancer.org\/cancer\/chronic-lymphocytic-leukemia\/about\/what-is-cll.html. Accessed March 31, 2023"},{"key":"5859_CR2","unstructured":"Cancer.Net ASCO - Knowledge conquers cancer Leukemia - Chronic Lymphocytic - CLL: Statistics. https:\/\/www.cancer.net\/cancer-types\/leukemia-chronic-lymphocytic-cll\/statistics. Accessed 03\/2023"},{"key":"5859_CR3","unstructured":"Institut National du Cancer Les LLC : points cl\u00e9s. https:\/\/www.e-cancer.fr\/Patients-et-proches\/Les-cancers\/La-prise-en-charge-de-la-leucemie-lymphoide-chronique\/Les-LLC-points-cles. Accessed 2023\/03"},{"issue":"11","key":"5859_CR4","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1182\/blood.V89.11.3909","volume":"89","author":"A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin\u2019s lymphoma","year":"1997","unstructured":"A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin\u2019s lymphoma (1997) The Non-hodgkin\u2019s lymphoma classification project. Blood 89(11):3909\u20133918","journal-title":"Blood"},{"key":"5859_CR5","unstructured":"Sant\u00e9 Publique France (2019) Estimations nationales de l\u2019incidence et de la mortalit\u00e9 par cancer en France m\u00e9tropolitaine entre 1990 et 2018. Volume 2 - H\u00e9mopathies malignes"},{"issue":"19","key":"5859_CR6","doi-asserted-by":"publisher","first-page":"3724","DOI":"10.1182\/blood-2010-05-282632","volume":"116","author":"M Sant","year":"2010","unstructured":"Sant M, Allemani C, Tereanu C, De Angelis R, Capocaccia R, Visser O, Marcos-Gragera R, Maynadie M, Simonetti A, Lutz JM, Berrino F (2010) Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood 116(19):3724\u20133734. https:\/\/doi.org\/10.1182\/blood-2010-05-282632","journal-title":"Blood"},{"issue":"17","key":"5859_CR7","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1182\/blood-2017-10-810044","volume":"131","author":"S O\u2019Brien","year":"2018","unstructured":"O\u2019Brien S, Furman RR, Coutre S, Flinn IW, Burger JA, Blum K, Sharman J, Wierda W, Jones J, Zhao W, Heerema NA, Johnson AJ, Luan Y, James DF, Chu AD, Byrd JC (2018) Single-agent ibrutinib in treatment-na\u00efve and relapsed\/refractory chronic lymphocytic leukemia: a 5-year experience. Blood 131(17):1910\u20131919. https:\/\/doi.org\/10.1182\/blood-2017-10-810044","journal-title":"Blood"},{"issue":"21","key":"5859_CR8","doi-asserted-by":"publisher","first-page":"5793","DOI":"10.1158\/1078-0432.Ccr-21-1497","volume":"27","author":"J Trotman","year":"2021","unstructured":"Trotman J, Buske C, Tedeschi A, Matous JV, MacDonald D, Tam CS, Tournilhac O, Ma S, Treon SP, Oriol A, Ping J, Briso EM, Arango-Hisijara I, Dimopoulos MA (2021) Single-Agent Ibrutinib for Rituximab-Refractory Waldenstr\u00f6m Macroglobulinemia: final analysis of the Substudy of the phase III innovate(TM) trial. Clin cancer Research: Official J Am Association Cancer Res 27(21):5793\u20135800. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-21-1497","journal-title":"Clin cancer Research: Official J Am Association Cancer Res"},{"issue":"6","key":"5859_CR9","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1182\/blood-2015-03-635326","volume":"126","author":"ML Wang","year":"2015","unstructured":"Wang ML, Blum KA, Martin P, Goy A, Auer R, Kahl BS, Jurczak W, Advani RH, Romaguera JE, Williams ME, Barrientos JC, Chmielowska E, Radford J, Stilgenbauer S, Dreyling M, Jedrzejczak WW, Johnson P, Spurgeon SE, Zhang L, Baher L, Cheng M, Lee D, Beaupre DM, Rule S (2015) Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. Blood 126(6):739\u2013745. https:\/\/doi.org\/10.1182\/blood-2015-03-635326","journal-title":"Blood"},{"key":"5859_CR10","unstructured":"HAS (2015) Commission de la Transparence. Avis du 17 juin 2015 - demande d\u2019inscription de la sp\u00e9cialit\u00e9 Imbruvica dans une nouvelle indication: lymphome \u00e0 cellules du manteau en rechute ou r\u00e9fractaire"},{"key":"5859_CR11","unstructured":"HAS (2016) Commission de la Transparence. Avis du 30 novembre 2016 Imbruvica - demande d\u2019inscription de la sp\u00e9cialit\u00e9 Imbruvica dans une nouvelle indication: macroglobulin\u00e9mie de Waldenstr\u00f6m. https:\/\/www.has-sante.fr\/portail\/plugins\/ModuleXitiKLEE\/types\/FileDocument\/doXiti.jsp?id=c_2742288"},{"issue":"11","key":"5859_CR12","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1038\/leu.2014.122","volume":"28","author":"SE Herman","year":"2014","unstructured":"Herman SE, Niemann CU, Farooqui M, Jones J, Mustafa RZ, Lipsky A, Saba N, Martyr S, Soto S, Valdez J, Gyamfi JA, Maric I, Calvo KR, Pedersen LB, Geisler CH, Liu D, Marti GE, Aue G, Wiestner A (2014) Ibrutinib-induced lymphocytosis in patients with chronic lymphocytic leukemia: correlative analyses from a phase II study. Leukemia 28(11):2188\u20132196. https:\/\/doi.org\/10.1038\/leu.2014.122","journal-title":"Leukemia"},{"issue":"12","key":"5859_CR13","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1182\/blood-2013-09-527853","volume":"123","author":"JA Woyach","year":"2014","unstructured":"Woyach JA, Smucker K, Smith LL, Lozanski A, Zhong Y, Ruppert AS, Lucas D, Williams K, Zhao W, Rassenti L, Ghia E, Kipps TJ, Mantel R, Jones J, Flynn J, Maddocks K, O\u2019Brien S, Furman RR, James DF, Clow F, Lozanski G, Johnson AJ, Byrd JC (2014) Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy. Blood 123(12):1810\u20131817. https:\/\/doi.org\/10.1182\/blood-2013-09-527853","journal-title":"Blood"},{"issue":"4","key":"5859_CR14","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1080\/17474086.2022.2067526","volume":"15","author":"BW Christensen","year":"2022","unstructured":"Christensen BW, Zaha VG, Awan FT (2022) Cardiotoxicity of BTK inhibitors: ibrutinib and beyond. Expert Rev Hematol 15(4):321\u2013331. https:\/\/doi.org\/10.1080\/17474086.2022.2067526","journal-title":"Expert Rev Hematol"},{"issue":"12","key":"5859_CR15","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1016\/j.jacep.2018.06.004","volume":"4","author":"S Ganatra","year":"2018","unstructured":"Ganatra S, Sharma A, Shah S, Chaudhry GM, Martin DT, Neilan TG, Mahmood SS, Barac A, Groarke JD, Hayek SS, Dani S, Venesy D, Patten R, Nohria A (2018) Ibrutinib-Associated Atrial Fibrillation. JACC Clin Electrophysiol 4(12):1491\u20131500. https:\/\/doi.org\/10.1016\/j.jacep.2018.06.004","journal-title":"JACC Clin Electrophysiol"},{"issue":"13","key":"5859_CR16","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1016\/j.jacc.2019.07.056","volume":"74","author":"JE Salem","year":"2019","unstructured":"Salem JE, Manouchehri A, Bretagne M, Lebrun-Vignes B, Groarke JD, Johnson DB, Yang T, Reddy NM, Funck-Brentano C, Brown JR, Roden DM, Moslehi JJ (2019) Cardiovascular Toxicities Associated with Ibrutinib. J Am Coll Cardiol 74(13):1667\u20131678. https:\/\/doi.org\/10.1016\/j.jacc.2019.07.056","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"5859_CR17","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.3324\/haematol.2021.278901","volume":"107","author":"JR Brown","year":"2022","unstructured":"Brown JR, Byrd JC, Ghia P, Sharman JP, Hillmen P, Stephens DM, Sun C, Jurczak W, Pagel JM, Ferrajoli A, Patel P, Tao L, Kuptsova-Clarkson N, Moslehi J, Furman RR (2022) Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients. Haematologica 107(6):1335\u20131346. https:\/\/doi.org\/10.3324\/haematol.2021.278901","journal-title":"Haematologica"},{"issue":"10","key":"5859_CR18","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s11912-021-01102-1","volume":"23","author":"M Sestier","year":"2021","unstructured":"Sestier M, Hillis C, Fraser G, Leong D (2021) Bruton\u2019s tyrosine kinase inhibitors and cardiotoxicity: more Than Just Atrial Fibrillation. Curr Oncol Rep 23(10):113. https:\/\/doi.org\/10.1007\/s11912-021-01102-1","journal-title":"Curr Oncol Rep"},{"issue":"Suppl 4","key":"5859_CR19","doi-asserted-by":"publisher","first-page":"S149","DOI":"10.1016\/j.respe.2017.05.004","volume":"65","author":"P Tuppin","year":"2017","unstructured":"Tuppin P, Rudant J, Constantinou P, Gastaldi-Menager C, Rachas A, de Roquefeuil L, Maura G, Caillol H, Tajahmady A, Coste J, Gissot C, Weill A, Fagot-Campagna A (2017) Value of a national administrative database to guide public decisions: from the systeme national d\u2019information interregimes de l\u2019Assurance Maladie (SNIIRAM) to the systeme national des donnees de sante (SNDS) in France. Rev Epidemiol Sante Publique 65(Suppl 4):S149\u2013S167. https:\/\/doi.org\/10.1016\/j.respe.2017.05.004","journal-title":"Rev Epidemiol Sante Publique"},{"issue":"11","key":"5859_CR20","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/0895-4356(94)90129-5","volume":"47","author":"M Charlson","year":"1994","unstructured":"Charlson M, Szatrowski TP, Peterson J, Gold J (1994) Validation of a combined comorbidity index. J Clin Epidemiol 47(11):1245\u20131251. https:\/\/doi.org\/10.1016\/0895-4356(94)90129-5","journal-title":"J Clin Epidemiol"},{"key":"5859_CR21","unstructured":"The Surveillance E aERSPotNCI (2021) Cancer Stat Facts: Leukemia\u2014Chronic Lymphocytic Leukemia (CLL). https:\/\/seer.cancer.gov\/statfacts\/html\/clyl.html. 2023"},{"key":"5859_CR22","doi-asserted-by":"publisher","unstructured":"Abrisqueta P, Loscertales J, Terol MJ, Ram\u00edrez Payer \u00c1, Ortiz M, P\u00e9rez I, Cuellar-Garc\u00eda C, Fern\u00e1ndez de la Mata M, Rodr\u00edguez A, Lario A, Delgado J, Godoy A, Argui\u00f1ano P\u00e9rez JM, Berruezo MJ, Oliveira A, Hern\u00e1ndez-Rivas J, Garc\u00eda Malo MD, Medina \u00c1, Garc\u00eda Martin P, Osorio S, Baltasar P, Fern\u00e1ndez-Zarzoso M, Marco F, Vidal Mance\u00f1ido MJ, Smucler Simonovich A, L\u00f3pez Rubio M, Jarque I, Suarez A, Fern\u00e1ndez \u00c1lvarez R, Lancharro Anchel A, R\u00edos E, Losada Castillo MDC, P\u00e9rez Persona E, Garc\u00eda Mu\u00f1oz R, Ramos R, Y\u00e1\u00f1ez L, Bello JL, Loriente C, Acha D, Villanueva M (2021) Real-World Characteristics and Outcome of Patients Treated With Single-Agent Ibrutinib for Chronic Lymphocytic Leukemia in Spain (IBRORS-LLC Study). Clinical lymphoma, myeloma & leukemia 21 (12):e985-e999. https:\/\/doi.org\/10.1016\/j.clml.2021.07.022","DOI":"10.1016\/j.clml.2021.07.022"},{"key":"5859_CR23","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14440","author":"M Allouchery","year":"2020","unstructured":"Allouchery M, Tomowiak C, Guidez S, Delwail V, Delaunay P, Lafay-Chebassier C, Salvo F, P\u00e9rault-Pochat MC (2020) Patterns of use and safety of ibrutinib in real-life practice. Br J Clin Pharmacol. https:\/\/doi.org\/10.1111\/bcp.14440","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"5859_CR24","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s44228-022-00020-8","volume":"4","author":"A Janssens","year":"2022","unstructured":"Janssens A, Berneman ZN, Offner F, Snauwaert S, Mineur P, Vanstraelen G, Meers S, Spoormans I, Bron D, Vande Broek I, Van Bogaert C, De Beleyr B, Smet A, Nielsen L, Wapenaar R, Andr\u00e9 M (2022) Effectiveness and safety of Ibrutinib for chronic lymphocytic leukemia in routine clinical practice: 3-Year follow-up of the Belgian Ibrutinib Real-World Data (BiRD) study. Clin Hematol Int 4(4):133\u2013143. https:\/\/doi.org\/10.1007\/s44228-022-00020-8","journal-title":"Clin Hematol Int"},{"key":"5859_CR25","unstructured":"Institut National du Cancer Les cancers en France - \u00e9dition 2017 - Cancer chez les personnes de 65 ans et plus. https:\/\/www.e-cancer.fr\/ressources\/cancers_en_france\/"},{"issue":"3","key":"5859_CR26","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1038\/s41375-019-0602-x","volume":"34","author":"JA Burger","year":"2020","unstructured":"Burger JA, Barr PM, Robak T, Owen C, Ghia P, Tedeschi A, Bairey O, Hillmen P, Coutre SE, Devereux S, Grosicki S, McCarthy H, Simpson D, Offner F, Moreno C, Dai S, Lal I, Dean JP, Kipps TJ (2020) Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL\/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study. Leukemia 34(3):787\u2013798. https:\/\/doi.org\/10.1038\/s41375-019-0602-x","journal-title":"Leukemia"},{"issue":"12","key":"5859_CR27","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1002\/ajh.25638","volume":"94","author":"T Munir","year":"2019","unstructured":"Munir T, Brown JR, O\u2019Brien S, Barrientos JC, Barr PM, Reddy NM, Coutre S, Tam CS, Mulligan SP, Jaeger U, Kipps TJ, Moreno C, Montillo M, Burger JA, Byrd JC, Hillmen P, Dai S, Szoke A, Dean JP, Woyach JA (2019) Final analysis from RESONATE: up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. Am J Hematol 94(12):1353\u20131363. https:\/\/doi.org\/10.1002\/ajh.25638","journal-title":"Am J Hematol"},{"issue":"21","key":"5859_CR28","doi-asserted-by":"publisher","first-page":"5657","DOI":"10.1182\/blood.V124.21.5657.5657","volume":"124","author":"G Binsah","year":"2014","unstructured":"Binsah G, Philip TA, Ferrajoli A, Jan B, Jain N, Wierda WG, O\u2019Brien S, Durand JB, Keating MJ (2014) An observational study of the occurrence of Atrial Fibrillation and Hypertension in patients treated with Ibrutinib. Blood 124(21):5657. https:\/\/doi.org\/10.1182\/blood.V124.21.5657.5657","journal-title":"Blood"},{"issue":"22","key":"5859_CR29","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1182\/blood.2019000840","volume":"134","author":"T Dickerson","year":"2019","unstructured":"Dickerson T, Wiczer T, Waller A, Philippon J, Porter K, Haddad D, Guha A, Rogers KA, Bhat S, Byrd JC, Woyach JA, Awan F, Addison D (2019) Hypertension and incident cardiovascular events following ibrutinib initiation. Blood 134(22):1919\u20131928. https:\/\/doi.org\/10.1182\/blood.2019000840","journal-title":"Blood"},{"key":"5859_CR30","doi-asserted-by":"publisher","first-page":"3268","DOI":"10.1182\/blood.V126.23.3268.3268","volume":"126","author":"D Gifkins","year":"2015","unstructured":"Gifkins D, Matcho A, Yang H, Xu Y, Gooden M, Wildgust M (2015) Incidence of Major Hemorrhage among CLL and MCL patients compared to the General Elderly Population: an analysis of the US SEER-Medicare Linked Database. Blood 126:3268\u20133268. https:\/\/doi.org\/10.1182\/blood.V126.23.3268.3268","journal-title":"Blood"},{"issue":"2","key":"5859_CR31","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1111\/bjh.14660","volume":"178","author":"JA Jones","year":"2017","unstructured":"Jones JA, Hillmen P, Coutre S, Tam C, Furman RR, Barr PM, Schuster SJ, Kipps TJ, Flinn IW, Jaeger U, Burger JA, Cheng M, Ninomoto J, James DF, Byrd JC, O\u2019Brien SM (2017) Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single-agent ibrutinib. Br J Haematol 178(2):286\u2013291. https:\/\/doi.org\/10.1111\/bjh.14660","journal-title":"Br J Haematol"},{"issue":"10","key":"5859_CR32","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.3324\/haematol.2017.171041","volume":"102","author":"JR Brown","year":"2017","unstructured":"Brown JR, Moslehi J, O\u2019Brien S, Ghia P, Hillmen P, Cymbalista F, Shanafelt TD, Fraser G, Rule S, Kipps TJ, Coutre S, Dilhuydy MS, Cramer P, Tedeschi A, Jaeger U, Dreyling M, Byrd JC, Howes A, Todd M, Vermeulen J, James DF, Clow F, Styles L, Valentino R, Wildgust M, Mahler M, Burger JA (2017) Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials. Haematologica 102(10):1796\u20131805. https:\/\/doi.org\/10.3324\/haematol.2017.171041","journal-title":"Haematologica"},{"issue":"5","key":"5859_CR33","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1111\/jth.13651","volume":"15","author":"JJ Shatzel","year":"2017","unstructured":"Shatzel JJ, Olson SR, Tao DL, McCarty OJT, Danilov AV, DeLoughery TG (2017) Ibrutinib-associated bleeding: pathogenesis, management and risk reduction strategies. J Thromb Haemostasis: JTH 15(5):835\u2013847. https:\/\/doi.org\/10.1111\/jth.13651","journal-title":"J Thromb Haemostasis: JTH"},{"issue":"6","key":"5859_CR34","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1093\/aje\/kwq433","volume":"173","author":"H Quan","year":"2011","unstructured":"Quan H, Li B, Couris CM, Fushimi K, Graham P, Hider P, Januel JM, Sundararajan V (2011) Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol 173(6):676\u2013682. https:\/\/doi.org\/10.1093\/aje\/kwq433","journal-title":"Am J Epidemiol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05859-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-024-05859-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05859-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,27]],"date-time":"2024-07-27T06:11:25Z","timestamp":1722060685000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-024-05859-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,5]]},"references-count":34,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["5859"],"URL":"https:\/\/doi.org\/10.1007\/s00277-024-05859-w","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,5]]},"assertion":[{"value":"17 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the French National Institute for Health Data (approval No 202441 on November 15 2018 and No 1491132 on April 2 2020). It was conducted using anonymized data, approved by the French Data Protection Authority (CNIL, approval No 918407 on December 21 2018 and No 918407V1 on June 26 2020). Written informed consent was not required for participation in this study, in accordance with national legislation and institutional requirements.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"SC reports personal fees from Gilead-Kite, Novartis, Roche, Abbvie, Sandoz, Sanofi, Janssen, Celgene-BMS, Takeda, Atara, Astra Zeneca, Pierre Fabre, Viatris. CM and FD are full time employees of PELyon. MD is full time employees of Janssen Cilag. NM was employed by Janssen Cilag when this study was performed. GdP reports personal fees from UCB, Janssen, Abbott, Alexion, Novartis, MSD, BMS, Astra Zeneca, Astellas, Moderna, Boehringer Ingelheim, EFPIA. VL reports personal fees from Janssen, Astra Zeneca, CSL Behring, BeiGene.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}